৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Indication
Primary biliary cholangitis (PBC): Indicated for use in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA for at least 1 year, or as monotherapy in adults who are unable to tolerate UDCA.
Administration
May be taken with or without food.
If taken with bile-acid binding resins, separate the dose by at least 4 hours.
Contraindication
Complete biliary obstruction.
Mode of Action
This medicine is a Farnesoid X receptor (FXR) agonist.
FXR is a nuclear receptor found in the liver, intestine, kidney, and adipose tissue. It regulates genes involved in bile acid synthesis, lipid metabolism, and glucose balance.
Activation of FXR reduces the production of bile acids and increases their removal from liver cells, thereby protecting liver cells from damage.
Precaution
Risk of liver failure and hepatic decompensation has been reported, especially in patients with advanced liver disease (Child-Pugh Class B or C) when taken more frequently than recommended.
Monitor liver enzymes and signs of worsening liver function such as kidney issues or dehydration.
Higher doses (more than 10 mg/day) may increase the risk of serious liver-related side effects such as jaundice, ascites, and disease flare.
Lactation:
It is unknown whether the drug passes into breast milk. Consider the benefits of breastfeeding along with the mother’s need for treatment and potential risks to the infant.
Side Effects
More than 10%:
Itching (pruritus)
Fatigue
Severe itching
Reduced HDL cholesterol
Abdominal pain or discomfort
1–10%:
Rash
Throat pain
Dizziness
Constipation
Swelling (edema)
Palpitations
Fever
Thyroid abnormalities
Eczema
Interaction
Bile-acid binding resins may reduce absorption and effectiveness.
Warfarin: May decrease INR, so monitoring is required.
CYP1A2 substrates (e.g., theophylline, tizanidine): May increase drug levels—monitor carefully.
Avoid use with bile salt efflux pump (BSEP) inhibitors (e.g., cyclosporine), as they may worsen bile salt accumulation in the liver.






Primary Biliary Cholangitis\r\nIndicated for primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA for at least 1 yr or as monotherapy in adults unable to tolerate UDCA
May take with or without food\r\n\r\nConcomitant bile-acid binding resin: Separate obeticholic acid dose by at least 4 hr
$4e
Complete biliary obstruction
Farnesoid X receptor (FXR) agonist\r\n\r\nFXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue that regulates a wide variety of target genes critically involved in the control of bile acid synthesis and transport, lipid metabolism, and glucose homeostasis\r\n\r\nFXR activation suppresses de novo synthesis of bile acids in hepatocytes as well as increasing transport of bile acids out of hepatocytes, thereby reducing exposure of the hepatocytes to bile acid
Hepatic decompensation and failure, in some cases fatal, reported in patients with PBC who have decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than the recommended starting dosage of 5 mg once weekly\r\n\r\nMonitor patients for elevations in liver enzymes and risks for hepatic decompensation (eg, worsening renal function, dehydration)\r\n\r\nDose response relationship observed in clinical trials for liver-related adverse reactions, including jaundice, worsening ascites, and primary biliary cholangitis flare (doses >10 mg/day)\r\n\r\nLactation\r\nUnknown if distributed in human breast milk\r\n\r\nConsider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition\r\n
>10%\r\nPruritus (56-70%)\r\nFatigue (19-25%)\r\nSevere pruritus (19-23%)\r\nReduced HDL-C (9-20%)\r\nAbdominal pain and discomfort (10-19%)\r\n\r\n1-10%\r\nRash (7-10%)\r\nOropharyngeal pain (7-8%)\r\nDizziness (7%)\r\nConstipation (7%)\r\nPeripheral edema (3-7%)\r\nPalpitations (3-7%)\r\nPyrexia (7%)\r\nThyroid function abnormality (4-6%)\r\nEczema (3-6%)\r\n\r\n
Bile-acid binding resins may reduce the absorption, systemic exposure, and efficacy of obeticholic acid\r\nCoadministration of warfarin and obeticholic acid has been shown to decrease the INR; monitor the INR and adjust warfarin dose accordingly\r\nCoadministration with CYP1A2 substrates (eg, theophylline, tizanidine) may increase exposure of CYP1A2 substrates; monitor CYP1A2 substrates with narrow therapeutic index\r\nAvoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) (eg, cyclosporine); BSEP inhibitors may exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms
N/A





